An interventional study of Myosuit robotic device in Heart Failure, Systolic, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.
Sponsored by German Heart Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure, Systolic with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure, Systolic · Germany.
Among the 11 studies in Heart Failure, Systolic with a site in Germany, this one is one of 2 that started in 2021, is one of 3 with no phase, and was the 9th registered.
230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.
Browse Heart Failure, Systolic studies →2 of the 11 studies in Heart Failure, Systolic with a site in Germany are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Germany, United States, Austria and 13 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 165 interventional studies indexed under Heart Failure, Systolic.
Median enrollment 30 across the 8 interventional studies, 65 across the 3 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 9 most frequent:
German Heart Institute is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
German Heart Institute has 2 studies filed under Heart Failure, Systolic — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Failure, Systolic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06675552AstraZenecaNon-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure, Systolic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will address the challenging task of remobilizing patients with advanced chronic lung or heart failure in a functional New York Heart Association class III-IV by using an externally physically-supported exosuit movement therapy. This soft, wearable robot (Myosuit) assists mobilization according to individual needs by activating neuromuscular feedback systems, promoting physical activity and preventing early physical exhaustion.
The feasibility, tolerance and safety of a Myosuit assisted training was shown in a feasibility trial. In the efficacy trial, patients will be randomized in a 2:1 ratio for an exosuit-supported or non-supported exercise training protocol, training 3 units per week for 8 weeks. Assessment of outcome will be performed by various functional, mobility and endurance tests, questionnaires and clinical parameters. Furthermore, the transfer of regained motor and balance skills to everyday life will be analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients perform exercise training with the Myosuit
Device: Myosuit robotic device
Patients perform exercise training without the Myosuit
Device: Myosuit robotic device
The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.
Exercise capacity improves more in patients who trained with robotic support
Exercise capacity is measured by six-minute walking test in meters
Time frame: 8 weeks
Exercise capacity improves more in patients who trained with robotic support
Exercise capacity is measured by six-minute walking test in meters
Time frame: 4 weeks
Mobility improves more in patients who trained with robotic support
Mobility is measured by timed-up-and-go tests in seconds
Time frame: 8 weeks
Mobility improves more in patients who trained with robotic support
Mobility is measured by timed-up-and-go tests in seconds
Time frame: 4 weeks
Balance improves more in patients who trained with robotic support
Balance is measured by berg balance tests via berg balance scale (0-56 points, the higher, the better).
Time frame: 8 weeks
Balance improves more in patients who trained with robotic support
Balance is measured by berg balance tests via berg balance scale(0-56 points, the higher, the better).
Time frame: 4 weeks
Exercise training improves quality of life
Quality of life is measured by Kansas City Cardiomyopathy Questionnaire
Time frame: 8 weeks
Heart failure Progression: Ejection fractions
Change of echocardiographic findings: ejection fraction (in %)
Time frame: 4 weeks
Heart failure Progression: Diameters
Change of echocardiographic findings: diameters (in mm)
Time frame: 8 weeks
Heart failure Progression: valve regurgitations
Change of echocardiographic findings: regurgitations (grad I-V)
Time frame: 8 weeks
Heart failure Progression: elevated filling pressures
Change of echocardiographic findings: end-diastolic pressure (elevated or normal)
Time frame: 8 weeks
Heart failure Progression: volume status
Change of echocardiographic findings: vena cava diameter (in mm)
Time frame: 8 weeks
Change in Heart failure biomarkers: NT-proBNP
Heart failure biomarkers: NT-proBNP
Time frame: 8 weeks
Change in Heart failure biomarkers: hsTroponin
Heart failure biomarkers: hsTroponin
Time frame: 8 weeks
Change in inflammatory biomarkers: hsCRP
Inflammatory biomarkers: NT-proBNP (in ng/mL)
Time frame: 8 weeks
Change in inflammatory biomarkers: IL-6
Inflammatory biomarkers: IL-6
Time frame: 8 weeks
Device acceptability
measured by a acceptability questionnaire (9 questions, Score 9 to 63, the higher, the better).
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Jan 2025, 38 months after the start.
Of 52 non-industry interventional studies with no phase under Heart Failure, Systolic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 38 months is above that.
Counting every sponsor, half of 56 studies reached it within 30 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
German Heart Institute